S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
Log in
NASDAQ:CBMG

Cellular Biomedicine Group Competitors

$18.08
-0.08 (-0.44 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.00
Now: $18.08
$18.26
50-Day Range
$17.82
MA: $18.29
$18.69
52-Week Range
$11.48
Now: $18.08
$19.50
Volume34,450 shs
Average Volume26,087 shs
Market Capitalization$352.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35

Competitors

Cellular Biomedicine Group (NASDAQ:CBMG) Vs. CLLS, ALEC, KRYS, ADVM, ALGS, and INBX

Should you be buying CBMG stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cellular Biomedicine Group, including Cellectis (CLLS), Alector (ALEC), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Aligos Therapeutics (ALGS), and Inhibrx (INBX).

Cellectis (NASDAQ:CLLS) and Cellular Biomedicine Group (NASDAQ:CBMG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 22.0% of Cellular Biomedicine Group shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 8.5% of Cellular Biomedicine Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cellectis and Cellular Biomedicine Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million61.15$-102,090,000.00($2.41)-13.73
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A

Cellular Biomedicine Group has lower revenue, but higher earnings than Cellectis.

Analyst Recommendations

This is a summary of current ratings and target prices for Cellectis and Cellular Biomedicine Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11402.50
Cellular Biomedicine Group02002.00

Cellectis currently has a consensus target price of $27.20, suggesting a potential downside of 17.80%. Cellular Biomedicine Group has a consensus target price of $19.00, suggesting a potential upside of 5.09%. Given Cellular Biomedicine Group's higher probable upside, analysts clearly believe Cellular Biomedicine Group is more favorable than Cellectis.

Profitability

This table compares Cellectis and Cellular Biomedicine Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Cellular Biomedicine GroupN/A-144.80%-61.68%

Volatility & Risk

Cellectis has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Summary

Cellectis beats Cellular Biomedicine Group on 8 of the 13 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 61.5% of Alector shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cellular Biomedicine Group and Alector's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A
Alector$21.22 million65.13$-105,390,000.00($1.71)-10.20

Cellular Biomedicine Group has higher earnings, but lower revenue than Alector.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cellular Biomedicine Group and Alector, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group02002.00
Alector00703.00

Cellular Biomedicine Group presently has a consensus price target of $19.00, suggesting a potential upside of 5.09%. Alector has a consensus price target of $33.6667, suggesting a potential upside of 93.04%. Given Alector's stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than Cellular Biomedicine Group.

Profitability

This table compares Cellular Biomedicine Group and Alector's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
Alector-757.78%-53.86%-31.44%

Risk & Volatility

Cellular Biomedicine Group has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Summary

Alector beats Cellular Biomedicine Group on 8 of the 13 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 27.4% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cellular Biomedicine Group and Krystal Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group02002.00
Krystal Biotech00503.00

Cellular Biomedicine Group presently has a consensus price target of $19.00, suggesting a potential upside of 5.09%. Krystal Biotech has a consensus price target of $97.25, suggesting a potential upside of 39.79%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Cellular Biomedicine Group.

Earnings & Valuation

This table compares Cellular Biomedicine Group and Krystal Biotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-57.98

Krystal Biotech has lower revenue, but higher earnings than Cellular Biomedicine Group.

Risk & Volatility

Cellular Biomedicine Group has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Cellular Biomedicine Group and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
Krystal BiotechN/A-10.72%-10.40%

Summary

Krystal Biotech beats Cellular Biomedicine Group on 8 of the 11 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

22.0% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 97.4% of Adverum Biotechnologies shares are held by institutional investors. 8.5% of Cellular Biomedicine Group shares are held by insiders. Comparatively, 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cellular Biomedicine Group and Adverum Biotechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group02002.00
Adverum Biotechnologies02802.80

Cellular Biomedicine Group currently has a consensus target price of $19.00, suggesting a potential upside of 5.09%. Adverum Biotechnologies has a consensus target price of $23.50, suggesting a potential upside of 68.82%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Cellular Biomedicine Group.

Earnings and Valuation

This table compares Cellular Biomedicine Group and Adverum Biotechnologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A
Adverum Biotechnologies$250,000.005,427.58$-64,490,000.00($1.01)-13.78

Cellular Biomedicine Group has higher revenue and earnings than Adverum Biotechnologies.

Risk & Volatility

Cellular Biomedicine Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Profitability

This table compares Cellular Biomedicine Group and Adverum Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
Adverum BiotechnologiesN/A-32.23%-28.02%

Summary

Adverum Biotechnologies beats Cellular Biomedicine Group on 9 of the 12 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

22.0% of Cellular Biomedicine Group shares are held by institutional investors. 8.5% of Cellular Biomedicine Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cellular Biomedicine Group and Aligos Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group02002.00
Aligos Therapeutics00403.00

Cellular Biomedicine Group currently has a consensus target price of $19.00, suggesting a potential upside of 5.09%. Aligos Therapeutics has a consensus target price of $30.50, suggesting a potential downside of 12.71%. Given Cellular Biomedicine Group's higher possible upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than Aligos Therapeutics.

Earnings and Valuation

This table compares Cellular Biomedicine Group and Aligos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than Cellular Biomedicine Group.

Profitability

This table compares Cellular Biomedicine Group and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
Aligos TherapeuticsN/AN/AN/A

Cellular Biomedicine Group (NASDAQ:CBMG) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

22.0% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 36.6% of Inhibrx shares are held by institutional investors. 8.5% of Cellular Biomedicine Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cellular Biomedicine Group and Inhibrx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellular Biomedicine Group02002.00
Inhibrx00403.00

Cellular Biomedicine Group currently has a consensus target price of $19.00, suggesting a potential upside of 5.09%. Inhibrx has a consensus target price of $28.6667, suggesting a potential downside of 18.58%. Given Cellular Biomedicine Group's higher possible upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than Inhibrx.

Earnings and Valuation

This table compares Cellular Biomedicine Group and Inhibrx's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellular Biomedicine Group$340,000.001,035.77$-49,980,000.00N/AN/A
InhibrxN/AN/AN/AN/AN/A

Inhibrx has lower revenue, but higher earnings than Cellular Biomedicine Group.

Profitability

This table compares Cellular Biomedicine Group and Inhibrx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellular Biomedicine GroupN/A-144.80%-61.68%
InhibrxN/AN/AN/A

Summary

Inhibrx beats Cellular Biomedicine Group on 5 of the 8 factors compared between the two stocks.


Cellular Biomedicine Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cellectis logo
CLLS
Cellectis
0.8$33.09-0.5%$1.41 billion$22.99 million-17.60News Coverage
ALEC
Alector
1.3$17.44-2.8%$1.38 billion$21.22 million-7.82
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.57-0.7%$1.37 billionN/A-47.01News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$13.92-12.6%$1.36 billion$250,000.00-10.96Insider Buying
High Trading Volume
News Coverage
Gap Down
ALGS
Aligos Therapeutics
1.8$34.94-10.9%$1.33 billionN/A0.00High Trading Volume
News Coverage
Gap Down
INBX
Inhibrx
1.4$35.21-8.3%$1.33 billionN/A0.00Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$18.32-1.6%$1.32 billion$356.07 million8.98
PCVX
Vaxcyte
1.8$24.71-4.2%$1.26 billionN/A0.00Insider Selling
News Coverage
PASG
Passage Bio
1.3$27.31-6.4%$1.24 billionN/A0.00High Trading Volume
News Coverage
Gap Up
TSHA
Taysha Gene Therapies
1.6$31.75-2.4%$1.20 billionN/A0.00
Mesoblast logo
MESO
Mesoblast
1.6$9.51-0.6%$1.12 billion$32.16 million-10.81Analyst Downgrade
TCRR
TCR2 Therapeutics
1.5$30.72-2.9%$1.03 billionN/A-12.69Analyst Upgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.1$26.33-2.5%$1.02 billion$42.74 million-292.56
BDTX
Black Diamond Therapeutics
1.6$26.95-1.9%$970.09 millionN/A-4.45Analyst Report
News Coverage
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.2$25.49-12.6%$962.60 million$4.36 million-8.91Analyst Report
High Trading Volume
News Coverage
Gap Up
CRTX
Cortexyme
1.3$31.22-5.9%$920.93 millionN/A-13.01
Compugen logo
CGEN
Compugen
1.4$13.26-1.8%$907.25 million$17.80 million-35.84
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.9$40.92-3.5%$831.49 millionN/A0.00
ATHA
Athira Pharma
1.8$24.32-6.5%$790.04 millionN/A0.00News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$9.75-2.5%$789.01 millionN/A-4.56Analyst Report
PRVL
Prevail Therapeutics
1.4$23.02-0.1%$788.34 millionN/A-10.01Analyst Downgrade
Vaxart logo
VXRT
Vaxart
1.3$7.05-2.0%$771.76 million$9.86 million-11.95
DTIL
Precision BioSciences
1.3$14.64-0.0%$768.31 million$22.24 million-7.28Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.79-2.6%$753.33 million$1.12 million-5.85News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$15.96-5.6%$747.17 million$69.89 million-3.81News Coverage
DBV Technologies logo
DBVT
DBV Technologies
0.8$6.51-0.9%$715.18 million$14.75 million-2.79Analyst Report
Curis logo
CRIS
Curis
0.9$11.55-6.8%$679.34 million$10 million-14.09Gap Up
Agenus logo
AGEN
Agenus
1.6$3.56-1.4%$676.93 million$150.05 million-3.27News Coverage
ORTX
Orchard Therapeutics
1.6$6.50-6.3%$632.22 million$2.51 million-3.94
SQZ
SQZ Biotechnologies
1.8$25.44-7.1%$628.80 millionN/A0.00
MeiraGTx logo
MGTX
MeiraGTx
1.4$15.74-3.1%$604.61 million$13.29 million-11.16News Coverage
HARP
Harpoon Therapeutics
1.5$23.76-1.7%$603.03 million$5.78 million-11.15
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.30-0.6%$574.93 millionN/A-1.36News Coverage
Surface Oncology logo
SURF
Surface Oncology
0.9$13.82-2.9%$562.16 million$15.36 million-20.94News Coverage
AVROBIO logo
AVRO
AVROBIO
1.7$14.93-2.3%$544.21 millionN/A-4.52Analyst Downgrade
News Coverage
FUSN
Fusion Pharmaceuticals
1.5$12.76-2.6%$532.42 millionN/A0.00
OPT
Opthea
1.7$12.48-5.0%$526.76 millionN/A0.00News Coverage
CDAK
Codiak BioSciences
1.4$27.35-3.9%$513.31 millionN/A0.00
OYST
Oyster Point Pharma
1.7$18.72-2.0%$484.25 millionN/A-5.39High Trading Volume
News Coverage
Gap Down
FRLN
Freeline Therapeutics
0.9$17.99-0.2%$466.32 millionN/A0.00Analyst Upgrade
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$8.86-2.8%$462.94 million$2.91 million-3.09
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.35-15.2%$452.31 million$147.87 million-3.77High Trading Volume
News Coverage
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$19.82-2.1%$439.59 millionN/A-17.23
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$3.39-2.1%$420.17 million$4.13 million-7.53
Cardiff Oncology logo
CRDF
Cardiff Oncology
1.7$11.14-4.1%$393.52 million$250,000.00-3.98Analyst Upgrade
High Trading Volume
News Coverage
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.33-3.2%$384.68 millionN/A-6.77
IPHA
Innate Pharma
1.1$4.70-2.8%$371.21 million$96.12 million-13.82
Solid Biosciences logo
SLDB
Solid Biosciences
1.3$6.04-0.2%$365.11 millionN/A-2.93Analyst Upgrade
News Coverage
OCGN
Ocugen
1.1$2.23-4.9%$361.32 millionN/A-1.51Increase in Short Interest
Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$10.83-1.0%$352.32 millionN/A-4.46Analyst Report
Decrease in Short Interest
Analyst Revision
News Coverage
This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.